Reports Q4 revenue $18.198M, consensus $16.82M. "Our strong performance in the fourth quarter reflects the positive impacts of our ongoing strategic initiatives such as the revamped sales force, innovative marketing programs, and continued physician and patient education. Performance was highlighted by record US Treatment Sessions revenue, while also achieving 64% year-over-year growth in US NeuroStar System revenue," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "We will continue to concentrate on execution for the remainder of the year in order to fuel growth and put ourselves in a position to achieve cash flow breakeven in 2024."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STIM:
- Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results
- Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Neuronetics expands NeuroStar Advanced Therapy’s TrakStar platform
- Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
